Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Factors for Postictal Agitation After Electroconvulsive Therapy in Older Adults With Depression.

Acta psychiatrica Scandinavica·2026
Same author

Sustained mood improvement with laughing gas exposure (SMILE): a randomised, placebo-controlled pilot trial of nitrous oxide for treatment-resistant depression: commentary, Kalmar et al.

BJPsych open·2026
Same author

Electroconvulsive Therapy in Movement Disorders: A Systematic Review.

The journal of ECT·2026
Same author

Does the Loss of Autobiographical Memories Contribute to the Therapeutic Effect of Electroconvulsive Therapy?

Acta psychiatrica Scandinavica·2026
Same author

Comparing the temporal pattern of symptom change across multiple treatments for depression.

Journal of affective disorders·2026
Same author

Which Residual Symptoms Predict Relapse in major Depression? A Scoping Review: Quels symptômes résiduels constituent des prédicteurs de rechute de dépression majeure? Un examen de la portée.

Canadian journal of psychiatry. Revue canadienne de psychiatrie·2026

Related Experiment Video

Updated: Jun 20, 2026

A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats
07:04

A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats

Published on: August 19, 2018

Kynurenic Acid Offers Added Value in Predicting ECT Outcomes in Depression.

Annelies Dellink, Jean-Baptiste Belge, Pascal Sienaert

    Neuropsychobiology
    |June 18, 2026
    PubMed
    Summary

    Kynurenic acid (KYNA) shows promise as a predictor for electroconvulsive therapy (ECT) effectiveness in treating severe depression. This biomarker may help personalize ECT treatment strategies for better patient outcomes.

    More Related Videos

    Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures
    10:38

    Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures

    Published on: May 9, 2020

    Related Experiment Videos

    Last Updated: Jun 20, 2026

    A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats
    07:04

    A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats

    Published on: August 19, 2018

    Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures
    10:38

    Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures

    Published on: May 9, 2020

    Area of Science:

    • Neuroscience
    • Psychiatry
    • Biomarker Research

    Background:

    • Electroconvulsive therapy (ECT) is highly effective for severe depression but lacks reliable predictors of treatment response.
    • Clinical factors have limited predictive value, necessitating multimodal models integrating biological markers.
    • Identifying predictive biomarkers can personalize ECT, optimize patient selection, and improve response rates.

    Purpose of the Study:

    • To assess the predictive value of plasma immune markers for ECT outcomes.
    • To determine the added contribution of these markers to existing clinical prediction models.
    • To identify potential biomarkers for personalized electroconvulsive therapy.

    Main Methods:

    • Prospective cohort study with 74 participants.
    • Development of multivariable linear and logistic regression models.
    • Assessed plasma immune markers and depressive symptom reduction (Inventory of Depressive Symptomatology - IDS-C).

    Main Results:

    • Kynurenic acid (KYNA) significantly predicted symptom reduction and remission post-ECT.
    • KYNA improved prediction accuracy when combined with clinical predictors.
    • KYNA showed stronger predictive value in unipolar depression, males, and patients without inflammation.

    Conclusions:

    • KYNA demonstrates potential as a predictive biomarker for ECT outcomes.
    • Further validation in diverse cohorts is needed for clinical integration.
    • KYNA may facilitate personalized treatment strategies for electroconvulsive therapy.